Toward immunotherapy with redirected T cells in a large animal model: Ex vivo activation, expansion, and genetic modification of canine T cells

Journal of Immunotherapy

Volumn 37, Issue 8, 2014, Pages 407-415

  Mata, Melinda ^a,b   Vera, Juan F ^a   Gerken, Claudia ^a,b   Rooney, Cliona M ^a,b   Miller, Tasha ^c   Pfent, Catherine ^c   Wang, Lisa L ^b   Wilson Robles, Heather M ^c   Gottschalk, Stephen ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Canine; CAR; HER2; Immunotherapy; Osteosarcoma; T cells

Indexed keywords

CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RETROVIRUS VECTOR; ERBB2 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA MODIFICATION; DOG; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CYTOTOXICITY; DISEASE MODEL; GENETICS; IMMUNOLOGY; K562 CELL LINE; LYMPHOCYTE ACTIVATION; METABOLISM; OSTEOSARCOMA; PROCEDURES; T LYMPHOCYTE; TRANSGENE; TRANSPLANTATION;

ANIMALS; ANTIGENS, CD28; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DOGS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; LYMPHOCYTE ACTIVATION; OSTEOSARCOMA; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TRANSGENES;

EID: 84919464843     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000052     Document Type: Article

References (42)

1. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011; 3: 95ra73.
2. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368: 1509-1518.
3. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012; 119: 2709-2720.
4. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008; 14: 1264-1270.
5. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011; 118: 6050-6056.
6. Graves SS, Storer BE, Butts TM, et al. Comparing total body irradiation high and low dose rates for minimum-intensity conditioning of dogs for DLA-identical marrow grafts. Biol Blood Marrow Transplant. 2013; 19: 1650-1654.
7. Lupu M, Storb R. Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model. Vet Comp Oncol. 2007; 5: 14-30.
8. Withrow SJ, Thrall DE, Straw RC, et al. Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma. Cancer. 1993; 71: 2484-2490.
9. Lindblad-Toh K, Wade CM, Mikkelsen TS, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature. 2005; 438: 803-819.
10. Singer J, Weichselbaumer M, Stockner T, et al. Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol Immunol. 2012; 50: 200-209.
11. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res. 2003; 9: 1284-1290.
12. Sorenmo KU, Krick E, Coughlin CM, et al. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLoS One. 2011; 6:e24167.
13. Komatsu T, Iwano H, Ebisawa M, et al. Pathological classification of canine mammary tumor based on quantifying mRNA levels of hormonal receptors, SATB1, and Snail in tissue and fine needle biopsy samples. J Vet Med Sci. 2012; 74: 719-726.
14. Chow KK, Naik S, Kakarla S, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2013; 21: 629-637.
15. Ahmed N, Salsman VS, Yvon E, et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009; 17: 1779-1787.
16. Ahmed N, Ratnayake M, Savoldo B, et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007; 67: 5957-5964.
17. Vera J, Savoldo B, Vigouroux S, et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006; 108: 3890-3897.
18. Gottschalk S, Edwards OL, Sili U, et al. Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive Immunotherapy of EBV-associated malignancies. Blood. 2003; 101: 1905-1912.
19. O'Connor CM, Sheppard S, Hartline CA, et al. Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep. 2012; 2: 249.
20. Vera JF, Brenner LJ, Gerdemann U, et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010; 33: 305-315.
21. Flint AF, U'Ren L, Legare ME, et al. Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Vet Pathol. 2004; 41: 291-296.
22. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 2008; 8: 147-156.
23. Mohseny AB, Hogendoorn PC, Cleton-Jansen AM. Osteosarcoma models: from cell lines to zebrafish. Sarcoma. 2012; 2012: 417271.
24. Gordon I, Paoloni M, Mazcko C, et al. The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med. 2009; 6:e1000161.
25. Shelton GD, Fujii Y, Lindstrom J. Mitogen stimulation of canine normal and myasthenia gravis lymphocytes. Vet Immunol Immunopathol. 1990; 24: 1-9.
26. Mizuno S, Fujinaga T, Kurosawa T. Augmentative effects of phytohemagglutinin-P on proliferation and cytotoxicity of interleukin-2-activated canine peripheral blood lymphocytes. Zentralbl Veterinarmed A. 1996; 43: 289-296.
27. Suhoski MM, Golovina TN, Aqui NA, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther. 2007; 15: 981-988.
28. Weissinger EM, Franz M, Voss C, et al. Expression of HSVTK suicide gene in primary T lymphocytes: the dog as a preclinical model. Cytokines Cell Mol Ther. 2000; 6: 25-33.
29. Ting-De Ravin SS, Kennedy DR, Naumann N, et al. Correction of canine X-linked severe combined immunodeficiency by in vivo retroviral gene therapy. Blood. 2006; 107: 3091-3097.
30. Georges GE, Storb R, Brunvand MW, et al. Canine T cells transduced with a herpes simplex virus thymidine kinase gene: a model to study effects on engraftment and control of graft-versus-host disease. Transplantation. 1998; 66: 540-544.
31. Singh H, Figliola MJ, Dawson MJ, et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cells. PLoS One. 2013; 8:e64138.
32. Huang G, Yu L, Cooper LJ, et al. Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 2012; 72: 271-281.
33. Modak S, Kramer K, Gultekin SH, et al. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res. 2001; 61: 4048-4054.
34. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999; 17: 2781-2788.
35. Rouleau C, Curiel M, Weber W, et al. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res. 2008; 14: 7223-7236.
36. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18: 843-851.
37. Ahmed N, Brawley V, Diouf O, et al. T cells redirected against HER2 for the adoptive immunotherapy for HER2-positive osteosarcoma. Cancer Res. 2012; 72: (8 Suppl): Abstract nr 3500.
38. Wels W, Harwerth IM, Zwickl M, et al. Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor. Biotechnology (NY). 1992; 10: 1128-1132.
39. Weijtens ME, Hart EH, Bolhuis RL. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther. 2000; 7: 35-42.
40. Harwerth IM, Wels W, Marte BM, et al. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem. 1992; 267: 15160-15167.
41. Jensen MC, Popplewell L, Cooper LJ, et al. Anti-transgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor re-directed T cells in humans. Biol Blood Marrow Transplant. 2010; 16: 1245-1256.
42. Maus MV, Haas AR, Beatty GL, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013; 1: 26-31.